Incyte Corporation
$23.73B- Market cap
- $25.32B
- Debt
- +$1.51B
- Cash
- −$3.10B
Capital structure 94% equity / 6% debt · EV / Revenue 4.62x · EV / EBITDA 13.50x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: INCY stock price near parity vs RIVN $126.75 current versus $102.41 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RIVN's multiple
Implied fair value · at INCY's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INCY FY 2025 (ended Dec 31, 2025) · RIVN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 4.62x · EV / EBITDA 13.50x
Capital structure 83% equity / 17% debt · EV / Revenue 3.67x
INCY carries the larger enterprise value at $23.73B against $19.80B; RIVN trades on the lower EV / Revenue multiple (3.67x vs 4.62x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
INCYTE CORPORATION · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Rivian Automotive, Inc. / DE · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.29x
0.97x
Net debt / EBITDA
Leverage against operating earnings
-0.90x
0.61x
Cash and equivalents
Liquid reserves on the balance sheet
$3.10B
$6.08B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
INCY vs AMGN
GILEAD SCIENCES, INC.
INCY vs GILD
VERTEX PHARMACEUTICALS INC / MA
INCY vs VRTX
REGENERON PHARMACEUTICALS, INC.
INCY vs REGN
BIOGEN INC.
INCY vs BIIB
Tesla, Inc.
INCY vs TSLA
Ford Motor Company
INCY vs F
General Motors Company
INCY vs GM
Lucid Group, Inc.
INCY vs LCID
Nikola Corp
INCY vs NKLA
Fisker Inc.
INCY vs FSR
$1.51B
$4.44B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.